Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Am J Med Genet A. 2013 Oct;161A(10):2609-13. doi: 10.1002/ajmg.a.36111. Epub 2013 Aug 15.
Schimke immuno-osseous dysplasia (SIOD, OMIM 242900) is a rare autosomal recessive multisystem childhood disorder characterized by short stature, renal failure, T-cell immunodeficiency, and hypersensitivity to genotoxic agents. SIOD is associated with biallelic mutations in SMARCAL1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily a-like 1), which encodes a DNA stress response enzyme with annealing helicase activity. Two features of SIOD causing much morbidity and mortality are bone marrow failure and T-cell deficiency with the consequent opportunistic infections. To address the safety and efficacy of bone marrow transplantation (BMT) in SIOD, we reviewed the outcomes of the only five SIOD patients known to us in whom bone marrow or hematopoietic stem cell transplantation has been attempted. We find that only one patient survived the transplantation procedure and that the existing indicators of a good prognosis for bone marrow transplantation were not predictive in this small cohort. Given these observations, we also discuss some considerations for the poor outcomes.
希姆克免疫骨发育不良(SIOD,OMIM 242900)是一种罕见的常染色体隐性多系统儿童疾病,其特征为身材矮小、肾衰竭、T 细胞免疫缺陷和对遗传毒性药物过敏。SIOD 与 SMARCAL1(SWI/SNF 相关基质相关肌动蛋白依赖性染色质调节因子亚家族 A 样 1)的双等位基因突变有关,该基因编码具有退火解旋酶活性的 DNA 应激反应酶。导致骨髓衰竭和 T 细胞缺乏以及随之而来的机会性感染的 SIOD 的两个特征导致了大量的发病率和死亡率。为了评估骨髓移植(BMT)在 SIOD 中的安全性和疗效,我们回顾了我们所知道的仅有的五名 SIOD 患者中尝试过骨髓或造血干细胞移植的患者的结果。我们发现只有一名患者在移植手术后存活下来,并且现有用于预测骨髓移植良好预后的指标在这个小队列中没有预测性。基于这些观察结果,我们还讨论了导致不良预后的一些因素。